Optimized combined low level light therapy and intense pulsed light therapy for the treatment of dry eye syndrome caused by Meibomian glands dysfunction.

ABSTRACT

Dry eye syndrome (DES) is a common disease that can lead to ocular discomfort, reduced visual acuity and reduced quality of life. Meibomian Gland dysfunction plays an important role in most cases. To evaluate the effects of "EyeLight", a novel device delivering combined intense pulsed light (IPL) and low-level light therapy (LLLT), we conducted a retrospective chart review of patients refractory to conventional medical treatment who were treated with "EyeLight" therapy at Laser Vision, Lebanon. Each patient received between 2 to 5 treatment sessions. Clinical measurements were obtained before and after each session, including tear film breakup time (TBUT), ME-CHECK-meiboscale and the ME-CHECK questionnaire to determine the need for an additional session and to monitor progress. The same clinical evaluation was performed 3 to 5 weeks after the final treatment. A total of 52 eyes were included. A significant improvement in objective clinical signs was found, with an increase in TBUT from 6.98±1.41s. to 9.27±1.25s. (P<0.001) and a decrease in ME-CHECK-meiboscale (P<0.001). A reduction of severity level on the ME-CHECK-meiboscale classification was observed in 90%, along with a significant improvement in subjective clinical signs on the ME-CHECK questionnaire (P<0.001). No ocular or facial adverse events were noted. "EyeLight" treatment of 2 to 5 sessions depending on the severity of MGD in each eye showed an improvement in objective clinical signs and subjective symptoms and therefore appears to be an effective treatment for DES related to MGD refractory to conventional treatment.